- $106.27m
- $146.71m
- $191.16m
Annual income statement for Ultralife, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 98.3 | 132 | 159 | 164 | 191 |
| Cost of Revenue | |||||
| Gross Profit | 24.6 | 29.4 | 39.2 | 42.3 | 46 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 98.2 | 132 | 149 | 154 | 197 |
| Operating Profit | 0.035 | 0.129 | 9.47 | 9.96 | -5.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.151 | -0.446 | 9.12 | 8.3 | -8.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.23 | -0.12 | 7.17 | 6.41 | -5.95 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.234 | -0.119 | 7.2 | 6.31 | -5.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.234 | -0.119 | 7.2 | 6.31 | -5.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.015 | 0.024 | 0.448 | 0.445 | 0.241 |